According to the Magic Pharmaceutical announcement, the cumulative deviation value of the closing price increase of the company's A-share shares exceeded 20% for three consecutive trading days on August 20, August 21, and August 24, 2026, which is an abnormal fluctuation in stock trading. After self-inspection and consultation with the controlling shareholders, there were no significant matters that should have been disclosed but not disclosed. From August 12 to August 24, 2026, the company's stock price had a cumulative increase of 91.49%. The latest TTM price-earnings ratio was 146.33 times, far higher than the level of about 51.00 times that of the same industry. The cumulative turnover rate was 137.74%. There is a risk of irrational speculation and rapid decline. The company's revenue in 2025 was 1,952 billion yuan, down 4.71% year on year; after deducting non-net profit of 34.869 million yuan, a year-on-year decrease of 50.97%. Revenue for the first quarter of 2026 was 423 million yuan, down 11.87% year on year; after deducting non-net profit of 126.7772 million yuan, a year-on-year decrease of 15.44%. Zhang Zhijun, the controlling shareholder and acting in concert, has reduced his holdings by a total of 14.362,400 shares, accounting for 2.69% of the total share capital.

According to the Magic Pharmaceutical announcement, the cumulative deviation value of the closing price increase of the company's A-share shares exceeded 20% for three consecutive trading days on August 20, August 21, and August 24, 2026, which is an abnormal fluctuation in stock trading. After self-inspection and consultation with the controlling shareholders, there were no significant matters that should have been disclosed but not disclosed. From August 12 to August 24, 2026, the company's stock price had a cumulative increase of 91.49%. The latest TTM price-earnings ratio was 146.33 times, far higher than the level of about 51.00 times that of the same industry. The cumulative turnover rate was 137.74%. There is a risk of irrational speculation and rapid decline. The company's revenue in 2025 was 1,952 billion yuan, down 4.71% year on year; after deducting non-net profit of 34.869 million yuan, a year-on-year decrease of 50.97%. Revenue for the first quarter of 2026 was 423 million yuan, down 11.87% year on year; after deducting non-net profit of 126.7772 million yuan, a year-on-year decrease of 15.44%. Zhang Zhijun, the controlling shareholder and acting in concert, has reduced his holdings by a total of 14.362,400 shares, accounting for 2.69% of the total share capital.